
bluebird bio, Inc. (Nasdaq: BLUE), relating to the proposed merger with Beacon Parent Holdings, L.P. Under the terms of the agreement, bluebird stockholders will receive $3.00 per share and a contingent value right per share of $6.84 in cash if bluebird’s current product portfolio achieves $600 million in net sales in a 12-month period before December 31, 2027.